Spyre Therapeutics (NASDAQ:SYRE) Issues Earnings Results

Spyre Therapeutics (NASDAQ:SYRE) released its earnings results on Thursday. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.08, Zacks reports.

Spyre Therapeutics Stock Performance

Shares of NASDAQ SYRE traded up $1.18 during trading on Friday, hitting $19.55. The company had a trading volume of 174,418 shares, compared to its average volume of 588,771. Spyre Therapeutics has a 12 month low of $18.26 and a 12 month high of $47.97. The firm has a market capitalization of $1.01 billion, a P/E ratio of -2.62 and a beta of 2.85. The stock has a 50 day simple moving average of $22.45 and a 200 day simple moving average of $26.83.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SYRE shares. Wedbush restated an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday, January 13th. Robert W. Baird increased their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $54.83.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).